淋巴细胞浸润与化疗反应评分作为晚期卵巢癌新辅助化疗患者的预后标志物
该回顾性研究纳入55例接受新辅助化疗(NACT)后行间歇性肿瘤减灭术(IDS)的晚期上皮性卵巢癌(EOC)患者,评估化疗反应评分(CRS)、淋巴细胞浸润等病理指标与预后的关系。结果显示网膜CRS可预测无进展生存期(PFS),淋巴细胞浸润与总生存期(OS)改善相关,且BRCA1/2突变与淋巴细胞浸润强相关。
要点
- 网膜CRS评分可预测NACT后EOC患者的PFS。
- 淋巴细胞浸润存在与OS改善相关。
- BRCA1/2突变与淋巴细胞浸润强相关。
核心结论
- CRS在NACT和IDS治疗的EOC患者中具有预测价值。
- 淋巴细胞浸润具有预后意义,并可能与贝伐珠单抗治疗存在交互作用。
研究设计与样本
- 回顾性研究,纳入2011至2016年在本机构治疗的EOC女性患者。
- 55例接受NACT的EOC患者被识别,其中48例具有完整临床和病理数据。
- 中位年龄63岁,IDS标本由研究病理学家审阅评估CRS、淋巴细胞浸润、坏死和有丝分裂。
主要发现
- 调整年龄、分期、减灭状态和IDS后贝伐珠单抗使用后,网膜CRS预测PFS:CRS 1 vs 2 vs 3的中位PFS分别为10.3、14、18.7个月(95% CI [7.4-15.7]、[12.2-22.9]、[13.5-31.3])。
- 淋巴细胞浸润的存在与OS改善相关(log-rank检验 P = 0.015)。
- 在淋巴细胞浸润患者中,IDS后贝伐珠单抗与更短的PFS相关。
- 25例患者已知BRCA状态,BRCA1/2突变的存在与淋巴细胞浸润强相关(P = 0.011),但与网膜CRS无关(P = 0.926)。
关键数值与推荐
- 网膜CRS评分1、2、3对应的中位PFS分别为10.3、14、18.7个月(95% CI [7.4-15.7]、[12.2-22.9]、[13.5-31.3])。
- 淋巴细胞浸润与OS改善相关(log-rank检验 P = 0.015)。
- BRCA1/2突变与淋巴细胞浸润相关(P = 0.011),与网膜CRS无关(P = 0.926)。
临床怎么用
- 网膜CRS评分可用于预测NACT后EOC患者的PFS,辅助预后评估。
- 淋巴细胞浸润状态可提供额外预后信息,并可能影响贝伐珠单抗治疗决策。
局限性
- 回顾性研究,样本量较小(55例,48例完整数据)。
- BRCA状态仅25例已知,存在数据缺失。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neoadjuvant Chemotherapy (NACT) followed by Interval Debulking Surgery (IDS) is an accepted frontline treatment in patients with advanced Epithelial Ovarian Cancer (EOC). Histopathologic assessment of tumor post NACT may provide a surrogate for response to treatment. The present study aims to characterize the pathological response and to examine its prognostic significance in these patients. Medical records of women with EOC treated in our institution from 2011 to 2016 were retrospectively identified. IDS specimens were reviewed by study pathologist and Chemotherapy Response Score (CRS), lymphocytic infiltration, necrosis and mitosis were assessed. 55 patients with EOC treated with NACT were identified and 48 had complete clinical and pathological data. Median age was 63 years. CRS assessed at omentum predicted PFS when adjusted for age, stage, debulking status (complete, optimal, suboptimal) and post IDS bevacizumab administration (mPFS CRS 1 vs 2 vs 3: 10.3-14-18.7 months 95% CI [7.4-15.7], [12.2-22.9], [13.5-31.3]). Presence of lymphocytic infiltration was associated with improved OS (log-rank test P = 0.015). Post IDS bevacizumab was associated with shorter PFS in patients with lymphocytic infiltration. BRCA status was known for 25 patients and presence of BRCA1/2 mutations was strongly correlated with lymphocytic infiltration (P = 0.011) but not CRS omentum (P = 0.926). Our study confirms the predictive value of CRS in EOC patients treated with NACT and IDS, but also demonstrates the prognostic significance of lymphocytic infiltration as well as its possible interaction with bevacizumab treatment.
引用
- Liontos M, Sotiropoulou M, Kaparelou M, et al. Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy. Gynecol Oncol. 2020. PMID: 32173048. doi:10.1016/j.ygyno.2020.03.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。